Cecilia B Chighizola, Rohan Willis, Gabriella Maioli, Savino Sciascia, Laura Andreoli, Olga Amengual, Massimo Radin, Maria Gerosa, Tatsuya Atsumi, Guilherme de Jesus, Laura Trespidi, D Ware Branch, Roberto Caporali, Danieli Andrade, Robert Roubey, Michelle Petri, Maria Laura Bertolaccini
In antiphospholipid syndrome (APS), the risk of clinical manifestations increases with higher titers of antiphospholipid antibodies (aPL). Despite the adoption of aPL titers in the classification approach to aPL-positive subjects, the value of longitudinal monitoring of those titers in the follow-up is still debated, being well studied only in systemic lupus erythematosus (SLE). The literature suggests that the rate of aPL positivity decreases during follow-up in primary APS, estimating that seroconversion occurs in between 8...
January 1, 2024: Autoimmunity Reviews